Literature DB >> 9390332

The effectiveness of acne treatment: an assessment by patients of the outcome of therapy.

J N Newton1, E Mallon, A Klassen, T J Ryan, A Y Finlay.   

Abstract

The impact of acne on quality of life can be profound. Although treatment improves the clinical features of acne, there is little information on its benefit from the patients' point of view. In this study, patients with acne referred to a dermatology clinic were sent questionnaires before being seen, and 4 and 12 months afterwards. Clinical severity was assessed by a dermatologist at baseline and at 4 months. Quality of life was assessed by patients using the Short Form 36 instrument (SF-36), the Dermatology Life Quality Index (DLQI), Rosenberg's measure of self-esteem and the General Health Questionnaire (GHQ-28). Of 90 available patients, 79 (89%) returned at least one follow-up questionnaire. The clinical acne grade improved substantially with treatment. There were also significant improvements either at 4 or 12 months in the DLQI, self-esteem. GHQ-28 and all five dimensions of the SF-36 that were impaired at baseline. Quality of life continued to improve between the 4- and 12-month follow-up questionnaires. Clinical and patient-assessed outcomes were significantly better in patients treated with isotretinoin. The study showed that disability caused by acne can be largely reversed by effective treatment. It also showed that patient-assessed measures of outcome can respond to changes over time and discriminate between treatments differing in effectiveness.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390332     DOI: 10.1111/j.1365-2133.1997.tb03787.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

1.  Oral isotretinoin: prescribers beware.

Authors:  N H Shear
Journal:  CMAJ       Date:  1999-06-15       Impact factor: 8.262

2.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.

Authors:  A G de Tiedra; J Mercadal; X Badía; J M Mascaró; R Lozano
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

3.  Psychological sequelae of acne vulgaris: results of a qualitative study.

Authors:  Parker Magin; Jon Adams; Gaynor Heading; Dimity Pond; Wayne Smith
Journal:  Can Fam Physician       Date:  2006-08       Impact factor: 3.275

4.  A Four-question Approach to Determining the Impact of Acne Treatment on Quality of Life.

Authors:  Peter Saitta; Steven K Grekin
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

Review 5.  Psychosocial effect of common skin diseases.

Authors:  Benjamin Barankin; Joel DeKoven
Journal:  Can Fam Physician       Date:  2002-04       Impact factor: 3.275

6.  Clindamycin Phosphate 1.2% and Benzoyl Peroxide 2.5% Gel for the Treatment of Moderate-to-severe Acne: An Update.

Authors:  Michael H Gold
Journal:  J Clin Aesthet Dermatol       Date:  2012-01

7.  A Comparison of Microneedling versus Glycolic Acid Chemical Peel for the Treatment of Acne Scarring.

Authors:  Fatima Ishfaq; Rohan Shah; Shawana Sharif; Nadia Waqas; Marielle Jamgochian; Babar Rao
Journal:  J Clin Aesthet Dermatol       Date:  2022-06

8.  Quality of life in patients with acne in Erbil city.

Authors:  Kameran Hassan Ismail; Khalis Bilal Mohammed-Ali
Journal:  Health Qual Life Outcomes       Date:  2012-06-06       Impact factor: 3.186

9.  Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.

Authors:  Katsuhiro Masago; Fumiko Imamichi; Yoshio Masuda; Noriko Ariga; Kiyomi Fujitomi; Yoko Fukumine; Kana Hatakenaka; Shiro Fujita; Nobuyuki Katakami
Journal:  Asia Pac J Oncol Nurs       Date:  2018 Oct-Dec

10.  Acne-specific quality of life questionnaire (Acne-QoL): translation, cultural adaptation and validation into Brazilian-Portuguese language.

Authors:  Cristhine de Souza Leão Kamamoto; Karime Marques Hassun; Ediléia Bagatin; Jane Tomimori
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.